<DOC>
	<DOCNO>NCT01908842</DOCNO>
	<brief_summary>The purpose study assess retention treatment induction buprenorphine/naloxone ( BNX ) sublingual tablet compare generic buprenorphine stabilization BNX sublingual tablet compare BNX film . Secondary objective include assessment treatment effect opioid withdrawal symptom , opioid craving , safety .</brief_summary>
	<brief_title>Efficacy BNX Sublingual Tablets Versus BNX Sublingual Film Treatment Opioid-Dependent Adults</brief_title>
	<detailed_description>This prospective , randomize , multicenter , parallel-group , non-inferiority study conduct 43 center United States August 2013 April 2014 . A non-inferior design use product contain active component , consider unethical include placebo arm . The study comprise induction phase 2 day stabilization phase 20 day , study visit schedule Days 1 , 2 , 3 , 4 , 8 , 15 , 22 . Eligible opioid-dependent patient randomly assign within 14 day screen induction either BNX sublingual tablet generic buprenorphine tablet 2 day . On Day 3 , patient initially allocate buprenorphine switch BNX film , whereas allocate BNX sublingual tablet continue treatment . On Day 15 , patient receive BNX film switch BNX sublingual tablet , BNX sublingual tablet switch BNX film . At final study visit Day 22 , patient offer option continue open-label follow-up study BNX sublingual tablet .</detailed_description>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>1 . Male/female 1865 year old 2 . Able read , comprehend &amp; sign informed consent form 3 . Meet opioid dependence criterion DSMIVTR past 12 month 4 . Have buprenorphinenegative UDS &amp; /or urine dipstick 5 . Prepared abstain opioids study drug &amp; addictive drug 6 . Negative urine pregnancy test 7 . Females childbearing potential use reliable method contraception . Females nonchildbearing potential ; surgically sterile postmenopausal define least 50 year age &amp; absence menses least 2 year 8 . Clearance prescribe MD withdrawn prescribe opioids subject receive opioids pain 9 . Lack clinically significant abnormality health assessment perform screen . Unclear case approve medical monitor 10 . At least mild withdrawal symptom ( COWS ≥9 ) 1 . Pregnant , lactate planning pregnant study 2 . Unwilling/unable comply requirement protocol ( e.g. , pending incarceration ) situation/condition may interfere participation study 3 . Prescribed treatment generic buprenorphine monotherapy within 90 day prior start treatment 4 . Daily dose methadone 30 mg past week receive last dose methadone le 30 hour prior treatment 5 . Participating clinical study medication deliver used investigational drug/device within last 30 day 6 . Allergy , sensitivity intolerance BUP , NAL related drug ; history drug hypersensitivity intolerance , opinion investigator , would compromise safety subject/study 7 . Staff , affiliate , family member staff directly involve study 8 . Serious untreated Axis I DSMIVTR psychiatric comorbidity ( actively suicidal homicidal , untreated schizophrenia ) 9 . Tongue/oral deformity may affect absorption drug product 10 . Current/history clinically significant medical disorder condition would jeopardize safety impact validity result . Unclear case discuss &amp; approve medical monitor 11 . HIVseropositive CD4+ count &lt; 200 , active AIDS defining infection last 120 day 12 . Have Class III/IV congestive heart failure , symptomatic myocardial ischemia history long QT syndrome ( immediate family member condition ) 13 . Currently take Class 1A antiarrhythmic medication ( e.g. , quinidine , procainamide , &amp; disopyramide ) Class III antiarrhythmic medication ( e.g. , sotalol , amiodarone , &amp; dofetilide ) 14 . Have uncontrolled hypertension , pulse oximetry ≤92 % clinically significant abnormality 12lead ECG , include correct QT ( QTc ) interval &gt; 450 m 15 . Severe liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Opioid</keyword>
	<keyword>Dependence</keyword>
	<keyword>agonist</keyword>
	<keyword>buprenorphine</keyword>
	<keyword>naloxone</keyword>
	<keyword>BUP/NAL</keyword>
</DOC>